Tuesday, November 03, 2015 12:25:40 PM
Utibron Neohaler--Courtesy of Novartis
Novartis ($NVS) announced FDA approval last week of its Utibron Neohaler as a long-term maintenance treatment for COPD via the delivery of the bronchodilating agents indacaterol and glycopyrrolate.
In addition, the agency approved the use of glycopyrrolate inhalation powder as a monotherapy, which will be delivered using the Seebri Neohaler. Both combination products will hit the market in early 2016, according to a company release.
The approval comes after a trial of 2,654 patients with COPD that consisted of two 12-week efficacy studies and a 52-week safety study, the release notes. Novartis notes that the approval does not cover asthma, and Utibron is not meant to replace rescue inhalers for sudden attacks.
"Patients have told us about the tremendous impact their COPD can have on everyday activities," said Christi Shaw, Novartis' U.S. country head, in a statement. "With this approval, the COPD community now has a new medicine that can help so many patients by improving not only their symptoms, but also their health-related quality of life. This means the possibility of doing things that matter to them."
Novartis says the Neohaler line of inhalers generates low resistance during delivery, making it easy to use.
Patients are instructed to insert an Utibron capsule inside the inhaler and then pierce it by squeezing buttons on the side of the device. Then, patients must put their mouth on the mouthpiece, inhale and hold their breath for 5 to 10 seconds. Once the capsule is empty of powder (this could take more than one breath), it's time to finish the 13-step process by removing the capsule from the inhaler, according to the product website.
Unfortunately, proper breathing technique and usage of inhalers have been shown to be challenging for patients, making simplification a drug delivery challenge for the future.
Novartis says almost 27 million Americans have COPD, making it the third leading cause of death in the U.S. Novartis hopes to grab a large share of a market expected to reach $14 billion by 2018.
The Utibron will compete with GlaxoSmithKline's ($GSK) Anoro and Breo Ellipta, as well as Boehringer's Stiolto Respimat in the combination drug COPD arena.
Recent NVS News
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 09/16/2024 12:44:34 PM
- Form F-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers • Edgar (US Regulatory) • 09/16/2024 12:12:17 PM
- Intel Secures $3.5 Billion Subsidy, Stellantis Backs EU Emissions Targets, BP and Apollo Reach $1 Billion Deal • IH Market News • 09/16/2024 10:03:27 AM
- Junior Biotech Utilizes AI To Shorten Drug Discovery Timelines, Ultimately Saving Lives • AllPennyStocks.com • 09/10/2024 10:53:00 PM
- Voyager Enters into License for Next-Generation Capsid, Bringing Partnered Portfolio of TRACER-Enabled Gene Therapies to 14 • GlobeNewswire Inc. • 09/05/2024 12:00:00 PM
- Lindy Biosciences stringe un accordo di licenza e collaborazione con Novartis per la somministrazione innovativa di farmaci multitarget • Business Wire • 08/28/2024 04:16:00 PM
- Lindy Biosciences conclut un accord de licence et de collaboration avec Novartis pour l’innovation en matière d’administration de médicaments à cibles multiples • Business Wire • 08/28/2024 04:07:00 PM
- Lindy Biosciences schließt Lizenzierungs- und Kooperationsvereinbarung mit Novartis für Wirkstoffabgabeinnovation für mehrere Zielmoleküle ab • Business Wire • 08/28/2024 04:06:00 PM
- Lindy Biosciences Enters Licensing and Collaboration Agreement With Novartis for Multi-target Drug Delivery Innovation • Business Wire • 08/28/2024 10:58:00 AM
- IBM Closes China Research Division, Uber Fined $324M, Starliner to Return Without Astronauts • IH Market News • 08/26/2024 12:58:21 PM
- Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 08/15/2024 08:30:06 PM
- Form SC TO-T/A - Tender offer statement by Third Party: [Amend] • Edgar (US Regulatory) • 08/13/2024 08:31:16 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/12/2024 07:30:35 PM
- Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN) • PR Newswire (US) • 08/07/2024 11:38:00 PM
- Google Faces Antitrust Ruling; SunPower Files for Bankruptcy and Business Sale – Latest Business News • IH Market News • 08/06/2024 09:44:42 AM
- Form SC TO-T/A - Tender offer statement by Third Party: [Amend] • Edgar (US Regulatory) • 08/02/2024 08:30:48 PM
- Form SC TO-T/A - Tender offer statement by Third Party: [Amend] • Edgar (US Regulatory) • 08/01/2024 08:30:53 PM
- Form SC TO-T/A - Tender offer statement by Third Party: [Amend] • Edgar (US Regulatory) • 07/31/2024 08:30:44 PM
- Form SC TO-T/A - Tender offer statement by Third Party: [Amend] • Edgar (US Regulatory) • 07/30/2024 08:30:54 PM
- Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 07/30/2024 11:00:00 AM
- Form SC TO-T/A - Tender offer statement by Third Party: [Amend] • Edgar (US Regulatory) • 07/29/2024 08:30:54 PM
- Form SC TO-T/A - Tender offer statement by Third Party: [Amend] • Edgar (US Regulatory) • 07/25/2024 08:30:58 PM
- Form SC TO-T/A - Tender offer statement by Third Party: [Amend] • Edgar (US Regulatory) • 07/18/2024 08:30:46 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/18/2024 10:09:04 AM
- TSMC Net Profit Hits $7.6B; Nokia Sees 32% Decline in Operating Profit; Novartis Boosts Outlook After Profit Surge • IH Market News • 07/18/2024 09:53:54 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM